Aarti Drugs Q3 net profit, revenue up but margins falter; declares ₹2 interim dividend

Aarti Drugs Ltd on Tuesday (February 3) reported a net profit of ₹40.5 crore for the third quarter, up 9.5% year-on-year from ₹37 crore. Revenue from operations grew 8.1% year-on-year to ₹601.7 crore, compared with ₹556.6 crore in the same period last year.

EBITDA for the quarter declined 11.8% to ₹54.7 crore from ₹61.7 crore in the year-ago period. EBITDA margin stood at 9%, down from 11% in the corresponding quarter of the previous year.

Also Read: Aarti Drugs targets 10-15% volume growth in FY26

Aarti Drugs informed that its board of directors has declared an interim dividend of ₹2 per equity share of ₹10 each (20%) for the financial year 2025-26. Monday, February 9, 2026, has been fixed as the record date for determining shareholder eligibility for the interim dividend payment.

Q2 numbers

The company had reported a strong set of numbers for the July-September quarter (Q2FY26), with net profit rising to ₹106 crore, nearly double the ₹52 crore recorded in the same period last year.

Revenue from operations increased 12% year-on-year to ₹2,100 crore, compared with ₹1,628 crore a year ago. EBITDA grew 47.7% to ₹291 crore, while the EBITDA margin improved to 13.9% from 12.1%, supported by better realisations and operational efficiencies.

Shares of Aarti Drugs Ltd ended at ₹393.40, up by ₹9.95, or 2.59%, on the BSE.

For LIVE Updates on Q3 results click here